These innovative agents represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://jessekstl241421.bloggazzo.com/37925447/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide